Deals channel feed

In­dia’s Lupin bags Sym­bio­mix and its new­ly ap­proved an­tibi­ot­ic for $150M-plus

8 years ago

Shov­ing Re­genxbio aside, Ul­tragenyx’s Emil Kakkis clos­es Di­men­sion buy­out deal with 400% pre­mi­um

8 years ago

With an FDA de­ci­sion loom­ing, Dy­navax is shop­ping a deal on Hep­lisav — re­port

8 years ago

Buy­out buzz: No­var­tis has been kick­ing the tires at AAA as FDA re­views Lu­tathera — re­port

8 years ago

Sanofi's Elias Zer­houni says his R&D group is ready to stand alone — but big M&A and part­ner­ships still loom large

8 years ago

With CRO con­sol­i­da­tion in full swing, Catal­ent inks a $950M deal to ac­quire Cook Pharmi­ca and sig­nals an ap­petite for more

8 years ago
Outsourcing

Bid­ding war erupts over Di­men­sion’s gene ther­a­py pipeline as Ul­tragenyx coun­ters Re­genxbio deal

8 years ago

Gene ther­a­py start­up Rock­et Phar­ma re­verse merges with trou­bled In­otek af­ter $25M raise

8 years ago

Mer­ck snaps up a Ger­man im­muno-on­col­o­gy up­start in a $603M bolt-on deal

8 years ago

Here’s the in­side ac­count of Gilead­'s 11-week sprint to its $12B Kite buy­out

8 years ago

Em­bold­ened by re­cent R&D suc­cess­es, Mer­ck KGaA looks at sell­ing off $1B-plus con­sumer di­vi­sion

8 years ago
Pharma

The top 10 bio­phar­ma CROs in the world—mid-2017 edi­tion

8 years ago
Outsourcing
Special

Dai­ichi Sankyo dous­es a puz­zling re­port about an As­traZeneca buy­out of­fer

8 years ago

Div­ing deep in­to CAR-T, Gilead forges $12B buy­out deal for Kite Phar­ma

8 years ago

Re­genxbio bags one of its gene ther­a­py vec­tor part­ners, buy­ing out a strug­gling Di­men­sion

8 years ago

Paratek shares soar as the an­tibi­ot­ic de­vel­op­er posts a ‘for sale’ sign

8 years ago

Biotech M&A bare­ly show­ing sign of a pulse so far in 2017

8 years ago

Melin­ta will beef up its an­tibi­otics pipeline af­ter a merg­er with trou­bled Cem­pra

8 years ago

Mallinck­rodt bags late-stage in­fan­tile jaun­dice drug in $425M In­faCare buy­out deal

8 years ago

Lab­Corp nabs Chiltern, boost­ing its big Co­v­ance CRO group to 20K-plus staffers in $1.2B deal

8 years ago
Outsourcing

Evotec ex­pands glob­al dis­cov­ery, de­vel­op­ment ops with $300M Ap­tu­it buy­out

8 years ago
Outsourcing

Mit­subishi Tan­abe bags Neu­ro­Derm and its PhI­II Parkin­son’s pro­gram for $1.1B

8 years ago

What's hold­ing back biotech M&A? SVB tracks a trend and calls a come­back

8 years ago
Financing

Biotech M&A? No­var­tis chief Jimenez says he’s stick­ing to the un­der-$1B aisle for now

8 years ago
First page Previous page 111112113114115116117 Next page Last page
A service from the Financial Times